Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer-8-year results of the breast international group 02-98 phase III trial

Annals of Oncology

Volumn 24, Issue 5, 2013, Pages 1203-1211

  Oakman, C ^a   Francis, P A ^b,c,d   Crown, J ^e   Quinaux, E ^f   Buyse, M ^f   De azambuja, E ^g   vila, M Margeli ^h   Andersson, M ⁱ   Nordenskjold B ^j   Jakesz, R ^k   Thurlimann B ^l,m   Gutierrez J ⁿ   Harvey, V ^o   Punzalan, L ^g   Dell'Orto, P ^p   Larsimont, D ^g   Steinberg, I ^q   Gelber, R D ^r   Piccart Gebhart, M ^g   Viale, G ^p   Di Leo, A ^a   more..

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c Australian New Zealand Breast Cancer Trials Group   (Australia)

^d International Breast Cancer Study Group   (Switzerland)

^e All Ireland Cooperative Oncology Research Group   (Ireland)

^f INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^g JULES BORDET INSTITUTE   (Belgium)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ Danish Breast Cancer Cooperative Group   (Denmark)

^j LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^k MEDICAL UNIVERSITY OF VIENNA   (Austria)

^l CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^m SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

ⁿ CLÍNICA LAS CONDES   (Chile)

^o AUCKLAND CITY HOSPITAL   (New Zealand)

^p UNIVERSITY OF MILAN   (Italy)

^q Sanofi Oncology   (United States)

^r DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

Adjuvant; Breast cancer; Chemotherapy; Docetaxel; Doxorubicin; Sequential

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; METHOTREXATE;

ADULT; AGED; ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE SEQUENCE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 84877129418     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds627     Document Type: Article

References (33)

1. Bonadonna G, Moliterni A, Zambetti M et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 2005; 330: 217.
2. Poole CJ, Earl HM, Hiller L et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 2006; 355: 1851-1862.
3. Levine MN, Pritchard KI, Bramwell VH et al. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 2005; 23: 5166-5170.
4. Chan S, Friedrichs K, Noel D et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 2341-2354.
5. Francis P, Crown J, Di Leo A et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 2008; 100: 121-133.
6. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
7. Cheang MC, Chia SK, Voduc D et al. Ki-67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-750.
8. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986; 70: 163-169.
9. Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21: 976-983.
10. Mamounas EP, Bryant J, Lembersky B et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005; 23: 3686-3696.
11. Roche H, Fumoleau P, Spielmann M et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006; 24: 5664-5671.
12. Martin M, Pienkowski T, Mackey J et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352: 2302-2313.
13. Martin M, Segui MA, Anton A et al. Adjuvant docetaxel for high-risk, nodenegative breast cancer. N Engl J Med 2010; 363: 2200-2210.
14. Jones S, Holmes FA, O'Shaughnessy J et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol 2009; 27: 1177-1183.
15. Fountzilas G, Skarlos D, Dafni U et al. Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2005; 16: 1762-1771.
16. Goldstein LJ, O'Neill A, Sparano JA et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 2008; 26: 4092-4099.
17. Ellis P, Barrett-Lee P, Johnson L et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 2009; 373: 1681-1692.
18. Roché H, Allouache D, Romieu G et al. Five-Year Analysis of the FNCLCCPACS04 Trial: FEC100 vs ED75 for the Adjuvant Treatment of Node Positive Breast Cancer. Cancer Research 2009; 69 (24 Suppl): Abstract nr 602.
19. Janni W, Harbeck N, Sommer H et al. Sequential Treatment with Epirubicin/ Cyclophosphamide, Followed by Docetaxel Is Equieffective, but Less Toxic Than FEC120 in the Adjuvant Treatment of Breast Cancer Patients with Extensive Lymph Node Involvement: The German ADEBAR Phase III Study. Cancer Research 2009; 69 (24 Suppl): Abstract nr 604.
20. De Laurentiis M, Cancello G, D'Agostino D et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008; 26: 44-53.
21. Laporte S, Jones S, Chapelle C et al. Consistency of Effect of Docetaxel-Containing Adjuvant Chemotherapy in Patients with Early Stage Breast Cancer Independent of Nodal Status: Meta-Analysis of 12 Randomized Clinical Trials. Cancer Research 2009; 69 (24 Suppl): Abstract nr 605.
22. Early Breast Cancer Trialists' Collaborative Group. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012; 379: 432-434.
23. Sparano JA, Wang M, Martino S et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358: 1663-1671.
24. Harvey V, Mouridsen H, Semiglazov V et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 2006; 24: 4963-4970.
25. Coudert B, Campone M, Spielmann M et al. Benefit of the Sequential Administration of Docetaxel after Standard FEC Regimen for Node-Positive Breast Cancer: Long-Term Follow-Up Results of the FNCLCC-PACS 01 Trial. Cancer Research 2009; 69 (24 Suppl): Abstract nr 603.
26. Cognetti F, De Laurentiis M, De Matteis L et al. Sequential epirubicin-docetaxel- CMF as adjuvant therapy for node-positive early stage breast cancer: updated results of the TAXit216 randomized trial. Annals of Oncology 2008; 19: viii77-viii88.
27. Swain SM, Jeong JH, Geyer CE, Jr et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 2010; 362: 2053-2065.
28. Eiermann W, Pienkowski T, Crown J et al. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol 2011; 29: 3877-3884.
29. Martin M, Mackey J, Pienkowski T et al. Ten-Year Follow-Up Analysis of the BCIRG 001 Trial Confirms Superior DFS and OS Benefit of Adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC (fluorouracil, Doxorubicin, Cyclophosphamide) in Women with Operable Node-Positive Breast Cancer. Cancer Research 2010; 70: (suppl. abstr S4-3).
30. Hugh J, Hanson J, Cheang MC et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009; 27: 1168-1176.
31. Dowsett M, Nielsen TO, A'Hern R et al. Assessment of Ki-67 in Breast Cancer:Recommendations from the International Ki-67 in Breast Cancer Working Group. J Natl Cancer Inst, 2011; 103: 1656-1664.
32. Jacquemier J, Penault-Llorca F, Mnif H et al. Identification of a basal-like subtype and comparative effect of epirubicin-based chemotherapy and sequential epirubicin followed by docetaxel chemotherapy in the PACS 01 breast cancer trial: 33 markers studied on tissue-microarrays (TMA). J Clin Oncol 2006; 24: (suppl. abstr 2509).
33. Coates AS, Colleoni M, Goldhirsch A. Is adjuvant chemotherapy useful for women with luminal A breast cancer?. J Clin Oncol 2012; 30: 1260-1263.